<SEC-DOCUMENT>0001193125-13-349170.txt : 20130828
<SEC-HEADER>0001193125-13-349170.hdr.sgml : 20130828
<ACCEPTANCE-DATETIME>20130828081032
ACCESSION NUMBER:		0001193125-13-349170
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20130828
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20130828
DATE AS OF CHANGE:		20130828

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GALECTIN THERAPEUTICS INC
		CENTRAL INDEX KEY:			0001133416
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				043562325
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31791
		FILM NUMBER:		131064303

	BUSINESS ADDRESS:	
		STREET 1:		4960 PEACHTREE INDUSTRIAL BOULEVARD
		CITY:			NORCROSS
		STATE:			GA
		ZIP:			30071
		BUSINESS PHONE:		678-620-3186

	MAIL ADDRESS:	
		STREET 1:		4960 PEACHTREE INDUSTRIAL BOULEVARD
		CITY:			NORCROSS
		STATE:			GA
		ZIP:			30071

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PRO PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20010612
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d590651d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>PURSUANT TO SECTION 13 OR 15(d) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>OF THE SECURITIES EXCHANGE ACT OF 1934
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of earliest event reported): August&nbsp;28, 2013 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>GALECTIN THERAPEUTICS INC. </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact name of registrant as specified in its charter) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Nevada</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>001-31791</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>04-3562325</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or Other Jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of Incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(IRS Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>4960 PEACHTREE INDUSTRIAL BOULEVARD, Ste 240 </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>NORCROSS, GA 30071</B> </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of principal executive office) (zip code) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Registrant&#146;s
telephone number, including area code: (678)&nbsp;620-3186 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>N/A </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Former name or former address, if changed since last report) </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below): </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17&nbsp;CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17&nbsp;CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SECTION&nbsp;7 &#150; REGULATION FD </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;7.01 Regulation FD Disclosure. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On August&nbsp;28, 2013, Galectin
Therapeutics&nbsp;Inc. (the &#147;Company) issued the attached press release, which is being furnished and not filed, and is attached hereto as Exhibit 99.1.</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The information in this report is being furnished pursuant to this Item&nbsp;7.01 and shall not be deemed &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934 (the
&#147;Exchange Act&#148;) or otherwise subject to the liabilities of that section, and it shall not be deemed incorporated by reference in any filing under the Securities Act of 1933 or under the Exchange Act, whether made before or after the date
hereof, except as expressly set forth by specific reference in such filing to this report. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SECTION&nbsp;9 &#150; FINANCIAL STATEMENTS AND
EXHIBITS </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01 Financial Statements and Exhibits. </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) Financial Statements of Businesses Acquired. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Not applicable. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) Pro Forma Financial Information. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Not applicable. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) Shell Company Transactions. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:8%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Not applicable. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d) Exhibits. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:26pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1">Exhibit<BR>Number</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:37pt"><FONT STYLE="font-family:Times New Roman" SIZE="1">Description</FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release dated August 28, 2013</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 2 -
</FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, Galectin Therapeutics Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Galectin Therapeutics Inc.</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: August&nbsp;28, 2013</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Jack W. Callicutt</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Jack W. Callicutt</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Chief Financial Officer</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">- 3 -
</FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d590651dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px">


<IMG SRC="g590651logo.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Galectin Therapeutics Announces Update on Warrant Exercises </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Norcross, GA (August 28, 2013) &#150; Galectin Therapeutics Inc. (NASDAQ: GALT)</B>, the leading developer of therapeutics that target galectin
proteins to treat fibrosis and cancer, today announced all of the 710,834 common stock purchase warrants scheduled to expire on August&nbsp;25, 2013 have been exercised for total cash proceeds of $3 million. These proceeds add to the recently
announced $3 million private placement of 500,000 shares of unregistered common stock. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;We appreciate the continued showing of
confidence in Galectin Therapeutics by these recent investments,&#148; said Peter G. Traber, M.D., Chief Executive Officer, President and Chief Medical Officer, Galectin Therapeutics. &#147;This additional funding will enable us to accelerate
planning activities for initiation of a Phase 2 clinical trial in fatty liver disease (NASH) with advanced fibrosis, following our Phase 1 trial, including manufacturing and preclinical support studies for the trial.&#148; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Previously, the Company announced it had $5.1 million of non-restricted cash and cash equivalents available at June&nbsp;30, 2013. With the addition of
the $6 million in proceeds from the warrant exercises and private placement, the Company believes it has sufficient funding for operations and planned research and development through the second quarter of 2014. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About Galectin Therapeutics </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Galectin
Therapeutics (NASDAQ: GALT) is developing promising carbohydrate-based therapies for the treatment of fibrotic liver disease and cancer based on the Company&#146;s unique understanding of galectin proteins, key mediators of biologic function. We are
leveraging extensive scientific and development expertise as well as established relationships with external sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and
commercialization for our lead compounds in liver fibrosis and cancer. Additional information is available at <U>www.galectintherapeutics.com</U>. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Forward Looking Statements </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">This press release contains, in addition to historical
information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as &#147;may,&#148;
&#147;estimate,&#148; &#147;could,&#148; &#147;expect&#148; and others. They are based on our current expectations and are subject to factors and uncertainties which could cause actual results to differ materially from those described in the
statements. These statements include those regarding our expectation that the additional funds will allow us to obtain meaningful data from our current Phase 1 clinical trial and expedite activities antecedent to the start of the Phase 2 clinical
program, and the sufficiency of cash on hand to fund future operations and planned research and development through the second quarter of 2014. Factors that could cause our actual performance to differ materially from those discussed in the
forward-looking statements include, among others,&nbsp;that our plans, expectations and goals regarding the clinical trial are subject to factors beyond our control and provide no assurance of FDA approval of our drug development plans. Our clinical
trial may not produce positive results in a timely fashion, if at all, and any necessary changes during the course of the trial could prove time consuming and costly.&nbsp;We may have difficulty in enrolling candidates for testing,
</FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
which would impact our estimates regarding timing, and we may not be able to achieve the desired results. Any significant delays or unanticipated costs in the trial could delay obtaining
meaningful results from Phase 1 and/or preparing for Phase 2 with the current cash on hand. Upon receipt of FDA approval, we may face competition with other drugs and treatments that are currently approved or those that are currently in development,
which could have an adverse impact on our ability to achieve revenues from this proposed indication. Plans regarding development, approval and marketing of any of our drugs, including GR-MD-02, are subject to change at any time based on the changing
needs of our company as determined by management and regulatory agencies. To date, we have incurred operating losses since our inception, and our ability to successfully develop and market drugs may be impacted by our ability to manage costs and
finance our continuing operations. For a discussion of additional factors impacting our business, see our Annual Report on Form 10-K for the year ended December&nbsp;31, 2012, and our subsequent filings with the SEC.&nbsp;You should not place undue
reliance on forward-looking statements. Although subsequent events may cause our views to change, we disclaim any obligation to update forward-looking statements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>Contact: </B>Jack Callicutt, Chief Financial Officer, 678-620-3186, <U>ir@galectintherapeutics.com</U>. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Galectin Therapeutics and its associated logo is a trademark of Galectin Therapeutics Inc. </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g590651logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g590651logo.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`-`#*`P$1``(1`0,1`?_$`,0```$$`@,!````````
M```````'"`D*!`8#!0L"`0$``@,``P$``````````````P4$!@<!`@D*$```
M!@(`!`(%!P0,!Q$````!`@,$!08'"``1$@D3%/`A(Q4*,4%1D=$B%C(T%QAA
M<8&Q,V,U59;76!JA0B0E-K89P7*"E;4FUC=7=SA(>+@Y>3H1``$#`P,"`P,(
M"@,```````$``@,1!`4A$@8Q$T$B!U$R%&&Q(S05%C<(<8%"LC-SLW2T=9&A
M=O_:``P#`0`"$0,1`#\`OY*N$D"G.J8$TTR&444.8I$TTR%$QSG.<Q2D(0H"
M(B/(``.?!%$0X[SNNM_RY:L%Z8XKV%[A&1*&_/$Y!DM3Z;5Y7#./9=-0Z?NR
MX[#Y1NV,L*-7J@IF\--C-2!U1(<"%,*:@%(E'G.Y8QPXDWE]Q-2]I-/L?K+)
MI/<U7^&Q9E;!]4!PLFV;.,D9"UORCF,N+(E1PJ4AY6QLXR$;=0"L]3#Y")X]
M$V,PYDW)F0,1T&Z,+7=<8TG$N1;@WA2+/H9G3\Y-K:^Q=,L+*@F>O3:%ICZ2
M_<I`S<KF(V*DJ<"D71,<B6GQR?0;Z@^W@B/')]!OJ#[>")'<\YRK>O6,9_*]
MKJN5;C`5ORII*$PUBR[9CO9F[E8$CO6-$QY$3UHD&+`O-1TLBV,FV1**B@E*
M`CP1,Z[<'=7UD[IE:S%<]8&.325/#%XB<?SLODBILJ>I-S4M!!/E7@(I.=EI
M3W<V;&!-0SY)DOXO,`2Z0ZA(I)_')]!OJ#[>"(\<GT&^H/MX(CQR?0;Z@^W@
MB/')]!OJ#[>"(\<GT&^H/MX(CQR?0;Z@^W@B/')]!O\`!]O!$>.3Z#?4'V\$
M1XY/H-]0?;P1'CD^@WU!]O!$GN5\NXZP=CJV9:RO9FM,QU18P9FV6F0;OG+*
M%BP<(-!>.&\6U?R"J?F'*9.22*AN9@]7+F/$%S<P6<#KFY=M@8-30FFM.@J?
M^E=\;XYF^79RVXWQRW==9N[DV0Q-+6E[J%U`7N:T:`G5P&B9UBGNLZ"YUN#+
M'^%\^H94NL@43MJS1,<9=LDIX)3%(9VZ2C:`LG',$S&`#N')DFY.?WCAQ7LS
MN+E?VXI'/D]C62$_\!M5U+D7Y<_67B&,?FN4X;[/Q4?O2W%U91,J>@!=<C<X
MT-&M!<?`%2"%=$,F"G0J`&(!^DZ8D4`!+U=)DS<CE/R^4HAS`?5RY\6P-15<
M3(H:::>S5-KNNY.M^-IQ2M9!R,%+GTBBH,59*E>(ITHD`]/F&P.:R1-ZU$WJ
M!5$RB8_,;CRO"U+_`&@VF_\`VZ5W_B>W?]'>"+O*UO'JG<;#"U2M9C@I:PV&
M1;Q,-&(Q=G25?2#L_0W;)JNH-!LF90W^,<Y"A\XAP1?4-O1II86<Q(0VT6"7
MS&O0N0+'..RY-J:+>)K^)F4?)92FGRKF41(WC,<,)9LM.+&'HBDUR"Y%/J#@
MB<A^)J[_`#Y%?R'^)OSYM_H[_/G\)_)7\?\`P?[/!%3P^+*[D>4L35'"7;,U
MLGW=>RMN4BB[RS.P[H[*<9X>F+*%$K-#CGS90KN/2RS;R/4))5/I.:+B56@]
M23Y0."*S/HWIQB30C5O$FK>&("-AJQC:L1S.9DF3-%M(7F\K,FQKGD.S."$(
MM)V2W3A%'*ZRHB*:8IH)@1!%),A$ZF0CX^68/HF68LY2*E&;J.DXN1:HOHZ2
MCGR!VSV/D&3DBC9XR>-E3)JI*%,10AA*8!`>7!%`IVI-#0T)[@?=JI=*KMFB
M=>,D?J;Y&U[5E$9E>MP%3DZYFU.?Q)39B1%=F>!Q)9RN&+"-;K&]U0J\>F<I
M>L@G(I]%#D234654(DBBF=5994Y4TD4DRB=1550XE(FF0A1$3"(``!P1:U`7
M>E6M=RUJUQJME=,@YO&U?L4/-.&H`;H$7*$:\<JH`!_5]X`]?!%M)!^^7D/R
MF#Y/H$0X(JAOPFK5NQ@^[&R9HIMVC/N"6AJU;I%`B2#=NSFDD$4RAZBII)D`
MH!\P!P16Z73IJQ:N'SYRW9,FB)W#MX\72;-&J"11.HLX<KG31013*`B)C&``
M#Y^"+JX&RUNU,SR-7L,%98]-44%'U?EX^:9D7+ZS(G<QKERB54O/UE$W,."+
MN^"+7%+C4$9Y.JK6NLI6A8"BE6U9^)3GU0.43D\.&.["1/U$#F'),>8<$783
M<U#5F'E;%99B*KM>@H]W+3D].R#2(A86*8(G<OI.6E)!9NQCH]DV3,HJLL<B
M:9"B8P@`"/!$Q/MR;P0W<&P_E'/-+3A7&,8K9G.6),1V""(^*A=L9XML;:MU
MN^.1?.%SF<7`R2[Y/H*B3RJJ("D0X'#@BZ?<&L=P:1V#T[L6J^9<08TUOK^0
M@_6UKN1(V.4G;O5WDO!)MHJN/)&`EEG*\A!^\&;)!B\BG*4JX06.JJF'2G19
M.+-R7]L_'2,;8AWTH-*D5%>H)(VU`H00>NFHZ/Q"^]-[;CF9@YA9W5QR.6WI
M8/C<0R.3:ZA=1[1H_87;FR`L!:`#[TBYQ*4JAS"!$TRF.<YS`0B9"@)C&4.8
M0*0I2AS$1'D'+B]7.%U7OZ#]SC8O?41^'RMO.#/>\V/N4&G/EYH97Q_(`VY^
MKK\3IY_/P1<D3,1$\Q2E(*6C)N,6,<J,C#OVDFP5,F/2H5-XR67;G,0WJ$`,
M(@/!$TON`X)MNSNG.=M?:*X8,[3ERLQ=,C)&4.)(Z)))VNO^\9I]TB"BK6%B
MDEW9TR#UJE1Z"_>,'%9F+:6[QTEM#_$?M`^3SMJ?U"I/Z%U+T5YAC/3_`-4<
M1S3,![L=C9WSO:P5<\MAEV,;X`R/+6`G0%U3H"FUU^JZG]F[6JNX]Q32DWEA
MFP!%,">41O\`F.VL&J82UTR!9_+G73C&AUP$>13MF)%DVK-`I1`H365C!8Q=
MN(5>?><>KC[2?F'0*#U4]6>9>L'*)>3\ON72/)(@@:2(+6(FHB@CK1H`IN=[
M\CO/(YSC5,C4[M6R1IL9!*LXI2A_'ZRUTT%.JE\N`_FYIG\0IO3*"7Y50('K
M]?1\W&:N:)P.8][M6-@=8WR.4J$_?9+457C(K'+0P&F:_9@:E.VN=<O)F94H
MJMD$2F%8Q!74$IFRC94.?,B@Z#F```CS'D',>7+F/+UCR^;F/!$XC4?_`,4F
MOG_>W3/^5D>"*;_/W:?U?V3C(Z'R:^R<LRB[OGZ[MPA+1'1*RZ^RV0V>1,L5
MI^J6!7,]ID^[:>[58T_-%S$J'0<>,/2H4B?;^B&N?SA._P#55^B'\\;?Z.?S
MA^9?R[_'?P?\7P1><O\`$4N'\1\2IJA+6XYT*RU5T3DXA=Z`"T3J+++ZXRRJ
M/4'2+-.>;R8G`?5X@'X(O2O/^6;_`'QOWQX(FH[2[71VJ=>;VR<P/LSF.N$@
M[+8[!)Z\8K2RE^#HFK(M'3]>RQJ-CB)DBKEHY.JV29MGBJR;98>D!*`&(HL-
M9OB/=&MS;L_QQJKB/=S/-SAX@UAFX3'NN1Y,:_`%=H,1FY]^XN;2)@XPSYTF
M@15TND"JRA2$ZC#RX(E[WY[?N>-\=I=.#V;,4#%=NK$:TW?-E-75E;7'6'8;
M(K3Q7-`A+@C"$1@[9CB/<%:>;BI)Z5F0$W?6V=F<)"@10@_$=L>WSK%J^XR3
MI>3#.O'<0UGRABRS46P:?UV-HN2Z#%2=SC8"RQ&7)'"T0VB:Y7)*.DO%;L[B
MHW2>O$4DFQ%#JBDJ16R=5LC3V8M9-;<NVH&P6C*F!L.9(L@,D2-V83]YQ[7+
M/,^503`I$6WO&44Z"%``*7D`?)P15C?A/PYQW=K`/E'N&VT/K0F^"+1:SN`X
M[IW>0V\QKDO"^:MEM%>V_P!>.Z%K1BEG5);'E_S^C<)"GRF:=@:Q<;]0H+)+
M)G*5&PHUR+?C(QS5)!LX!L1<JZBY%O6[>`]JL:[*:H;>=FKMLYIP!D^BW)Y"
M;5XW9,-?,#X8V&P2J2*5;U:[T6KYE6I]BL#4Z3U!G(E8)R++S95P6%1LT%(B
M<5WY-_LYT'*6A_;%U1NDUAS.G<4RA5ZK>LQP@MT;KAG"4W=8"C2;FEO.I<D3
M=+`]E7_3)(]2K!K#.`0,1==%PB1/NR1V3.WY9M6L@:Z4O7S&-.MUEQ]8*[6-
MD)*IL[?L36<D.XM<M>S,^S5,&/E*P7R&M8(2ZSI68(H[63,F8Q4CB3@B2:P=
MOZ6A^S'-ZQ]PV^1&]62<!8.SC<$<H6]K802?62LUC),GB^04/)2HSEADJ!5Y
M%I')/I119PZ.T!=0!4Y&`BBF^%HT;U1S1VM\:YCR?AN%MN2X[/F6A9VIY.7!
MFZ2-5[1&.($WDHNQL(HPQZB9>D!;B!P*'6!O7S(D)^(5U<QW@KN8]E_+6.)7
M)K.1V,WHAWF5*[9<P90OU.E+#5L]Z^3\5.0-4O5KL4+2SIKWM^GY2'291Y$?
M"(FW3*D7@BGR[^^L&(\]]L_;2^9!C[0>Y:]ZZYKR?B>>K60+Y3AK]K@ZJ-@3
M6DH>JV2'K]O8/EZX@@LUF6C]`&YE"I%3,H8W!%'9\/\`Z-8]VI[3.GU_W0<I
M[-TEE6K[`84U]N[9RK@7%E1KV6<@0JCV:QJH[4KV4\G3LLW=K*SU@1?!&QIF
ML?&(,DT7"CPB1?7JBP?;D^*';:8ZIMW^+-3=MM1I#+=PU^AY:04Q7"7V+K&0
M)Q&S4VJ.W3IE6W*,SBY040;@F#=*4=MT@(U,FB0BN0<$5<#NR.)Q79N&;R/C
M!$-<5UK\.%/S!OX#B7L)Y91N'Y/B'DB"500]8]!0'Y`X(N+MYH:I+,<L?K,?
MHL%<KZG?@W])"C)-3P!;6#WW[G\X<O4GXH-O'Z?GZ.?!%*;2<9]N7),V%:H%
M3U[N-@%DYD0AZ\A&23_R#,R173P6Z!S&*W;F7(!C#R`!,`?*(<$6^V_6'2N@
M5:Q7B[8>P[5:=4862L=HLTY#L8^%K\##M57TI,2SYP<B+./CV:)U553B!2$*
M(CZ@X])'LB89)#1C14GV`+/Q>+R.;R,&(Q$,ESE+J5L4,4;2Y\DCR&L8QHU<
MYSB``-231-KQ9FGL_3>2:+$8?R;J!*94DK/$M,>QU.M-7>6E[;5G)2PR%?;-
M'BCE:54="`(E(`F$X^KC!9EL<][8V2M+W$`#74GH.GBNCY7T+]8\%C)\SF>,
MYFUQ5K$Z2:62UE9''&P5<][BT`-:-23T"E.'Y1Y_+\_%BN4KL."*II\49V?L
MG[U8NQMM]JG"/[#M)JO&2#%_1H%/JL^4<0FDOQ01I42EYK2%YQM9`<246P3Y
M*2#>0>I(@H[!JBH12T]I+N=XC[E^L5-N<+8HR)V*I%>BJQLY@^27)&W_`!EE
M2$03AK4M(55YY>8)4YZ<:+.8M]X(HG15\!0Q':#A!(B>AM5L7A_4W7[*6?,\
M7*#HF-Z!4)R4EI6>?M6'O%T2,=C&5J$1=*)J3-GLCPI6D<P;@HY>.E2)ID,8
MP!P14@?@FJI.M,B=Q"Y2U7G82.L%/UY&N2,G#/64=)LW=FS(\>$B))RT1;R!
M&XI(>)X!C%#F43!^3P12=]WG?G+MM[M^CO9M@LKV35S7;/\`'56W[)9FIDX>
MCY,R7`V]W?4(G#=&R*51%_086U*T,(1:0BU$9)U)3142JD(W,DX(M:^);-IY
MJUV;,N:68*B<=XWM,E8,&6*)PKBZ%\Y-QU;@LR49[*9"R<2OMY"0@HZ35;$0
M_$EI72--3"R:!7+EXL!1(I[>W?F#&,MJAH_BN,N<,_R$;0+63+!JNT54</4,
M=.,=5&JM;6Z713.P:1SRQ-%VB(**E465;+]!3`@J)"*OY\)58H:98]V<L5(-
M'_B[Y2MC1\JZ;KBK"SJ5I"*D2%25.<6;[W<KX2O+PU.@>DP])N1$DG:.K4CV
MW/B&^YEJ/G8YJBAO+^(<XZP6><,#&$RU&ER=:<F5R&K$BL8C24G4ZMD";;.$
M4S"<DC`.V_+K`H'(K>>P6?\`&.L6+YK+F7)AS$UF+>0T)'1\5'.9VV7.X6B3
M;05/H-"JS`IY:WWJY3[U%C&1C,AW#IPJ```%`QBD52#XEBE776SN!=I3NV#7
M9J8P;KUDW'N/\Z/XUBX?&H<?7\NM<B0Z\N@S*OY=.W0-DGF:"O/PO/L4FXG\
M1P@4Y%<GJ%NJ^0ZM7+W1+!$6ZEW&%C;+5+37G[>5@K#7YIHE(1,Q$R3-15J]
MCY!DX(JDH0PE,0P#P1,\R!F"J;2:A;DN,.(3-AAHVE[,83@+&+)+W!D6U5.@
MSE:GY3'+]HY>%L]29W59W!$?D`A'$G%NRH@=(B:JA%!W\)IDC'U7[*A;!9KK
M5JY`XPSIGQYD:;GIV,AXBCLDUH.RJ/K3(R#ENT@V2<"^2=BJX,F3P#@;GRX(
MD)^)XGX)/=CX?(5IF+0!ONFZL#@R[]LB1M!'RYJ<)9IP=14I$(H00./CG$J7
M(AO7]T>1%/EWFWC./[3O<<</W3=DW-IWGEH5=TJ1!(SJ1H,RPCVQ3J&*4SA\
M^<IHHD#[RBJA2%`3&`.")I/PR[]C(=D32(&#UJ]%C%YDCWH-5TUQ9OT=@,IG
M68N@3,86[M(BI3&3-R,!3`/+D(")%&UFBQ10?&4:FLG$C&H+,]%9RME(9\W!
M099YC39&;;1JQ#*`*,DX:2)5$T!Y*'2.0P`('*(D5BGN0;23VDVDFP&UU;@&
M%JD\%5J#O*E8DE#MVMAB&EVK#*R0GFB%,9D[E*Z]=H-W'28&[@Y%!*8"B42)
MOLBWUD[QNK.,]B]:,GPTJB\CEGM(N2:9%7M<D7:3=2RXKRI7VZAY.OS$2_*0
MCQHI_E#)R0%D?&05`5B*.1?MC;?)3!HHE*K+IJ544RV!&\U\(0Z0&Y>9#S"R
M,N1,2AU=)F@*?-T\_5P12+XXQY@'M/Z^92VAVCRA6H((:N"YOEY7,9O$PT0T
M,9W'X_H3%SX4I9K%9)5---%!%+SLJ^\%%%$`*4!(LW8G.T9M%V7<U;(PL`_J
MT)GGM_7O+4+6Y5PB[E(2&OV')&R149*+MRE;*232/D$R./#YI@L!@*(E`!'&
MO?JDO\MWS+KGH#^.'$?_`$>/_P`J-4(NU:`?[2+1_P!7_F4Q9_K(TXT.'ZU;
M_P!Q'^\%]R?S%_@3RS_0WG]%R]30WRC^V/[_`!T8]5^=I9_'A%B+?E_N!P1,
M3S3VT-$-@<C)9ER9K30ELSI'!7],]%5L.(<PN%"@<I3R&4L23=(O4ITE.(`#
ME^J'+D'+D`!P18L-VQ]%XVR0-QGL!1.6;95E$EZQ8MA[?D3964K+M$!!)_6U
M<^V[(R=>D4P'U.&1$%OGZN8<$3ZVS=NS;(,V;=!HT:I$0;-&J*;=LV13*!4T
M4&Z)2)(I$*``!2@``'!$S7;?MV:1;X)U7];C6_'N;'M'!PG4)^P(2D3;:ZU>
M+)N7<;%7*JR<#:FL.Z=)%549E>>5.J4#BF)PY\$7;5O0;2VH8,O.M5=UDQ!'
M8.R?&$B<E8_"HL73#(C9(I`:N+U*/0<V"VR[$R1#MG[]VX?-E4R*)*D.0I@(
MDKQKVG>W/B#%%PP?CO4_'$!B[($G`2UWK*R]IG3VIQ52R1*PTFYZPV&5LC^#
MKA9I[Y&-.\&.:"\7%)`HK*"8BU>([<O;OTU\SL#@30W'4#DBA"SDZ\WP33(^
M$O\`-2RCQ&,C(^)+[X@HAXN+F2Y_YP7(T0()U%#%*4QN(+J<VUNZ<,<\M'NM
MIN)Z4%2!7])`5ABK`9/(16+IH;=DA-9)21&P`$ESBT.=0`=&M))H`"2DTVA<
M:O;I3>9M?MC=#+7G>SZA5O&N79EN#O'A;Q2D<ILK7*U>9P??:_D6OWJ-N/E,
M?/5'!(5_'.O$;H$(950Z1>*8YR8231?"3F2W:USP'1D@.!(IY_,:`Z#7PZD+
M;QP1HQV.RLF3LH['*3S0P.<V<#?`8VO[GT1[;:RLHXU%"2:`%*#@36/37&^U
MD]CVNXFR?:\TX/QA0,LT_+.P66LD[$#`5?+$I?*?'?HDF,RY.R--T.=9N*!)
MLWYVK&)<F;'*4%ETE3<K*._9)?R8_:X21QL?72A:\N`IK6H+36H"UVXP%Q;\
M=MN2&2)UK<74UN&#=O9)`V)[MU6ANUS9F%I:YWB#0A2+7BB4K)]/L>/\C5"M
MWZAVZ+<PEKIUPA(ZR5:Q0[LH`ZC)N#EF[N-DF2P`'4FLF8O,`'ES`!XSE1*.
MVF]G'M_X[;OH6A8KR/3,>2;IV\>X7K&R^S<)@9PM)*&5D$1PM'9=;XW+%R*R
MIC+QY8X(];J$#("4P@)%(_5*G6:'6Z_2Z16H.G5"JQ+&!J]4K$0Q@J[7H.+;
MIM8Z'@X6,0;1\9&1[5,J:2"*9$TR````!P11P0?9C[958S58,]P.IM,A[S;;
M,RNEDA&$_?&N(YZYQLH,W&VF6P.E:BX7DIN-F#B[;*+0*@-G8^.D4BWW^"+;
M,F]I/MJYHN<[D++NE>"<EWBQR,C,3=HO-3_$TR\?2S]S)R*_G)=TZ4;)N9!V
MJL*:7AI`<XB4H<$6V9([>6A-XQ10</97UOQ-:,.8T?O6]!HMV:.9*H5Z1O=A
MCSK-V4?+2:C9PYGK,9J5NFMXIO-&3(B!3"4./5[VQC<\@-J!K[2:`?K)`'RJ
M2.*29VR)I<_:30"IHT%SCIX-:"XGP`).@7#K!IEJ-J_?,LU_7#3JOZYM#05:
MB)2XU&"AZY1\JQMJ06DY..K;*'L;QXLYJ[J)00E%7L<P4!95($%%R=1BQLE<
M^9\18]K6;:.--KJ@UVZU\O0U`^2JRI[.*&Q@O&SPR23&0.B;N[D6P@`R5:&_
M25JS:YV@.[::`IPY[,W:Q>SY[4]T2U^>6U1R1^>UNZ@=S:S/4BD32?#8UGIY
ML7:)$RE(KX_B$*4``0``XF6"D9[],1'0'92WR@8=HFPB(/7EO#Q3!(5#),HV
M,LU09,6:9E3J*BFV:H$(`F,8W(OK$1X(O)IU%WVW#T.N+B\ZE;`9!PM,2)FP
MST?6Y--S4;61H<#MD;C19I"4IEL2;^L$O>#%P*(&'PQ*(B/!%.6A\7OWBT8`
M(=2RZZ.I($/"&V+X*CBV`5.D"^;%NVGV]6\QS^]R",!+G_B<O5P10J[F=QW=
MKN!V-G8]N-AKWEXL2\<OJ[5Y%RSA,?51RZ(9%5:KX\K+2&I<$Z.V'PC.$&17
M*J8<E%#^L>"+U(L=_P#YI*9_]0<'_P"V9MQC7OU27^6[YEUST!_'#B/_`*/'
M_P"5&J6W:L_^2+1__P!2F+/]9&G&AP_6K?\`N(_W@ON3^8O\">6?Z&[_`*+E
MZFAOE']L?W^.C'JOSM+/X\(L1;\O]P."+BX(C@B."(X(C@B."(^CYOW>7['R
M_N\$4:&O\!D",[D.^&0YS%>2*]CK*N-=3:OCK($U7TFE6M,OA>,S"VOB31RG
M(+2#%)FXNK`C11VV;IO^:AD#'*3F.N6!E&=O)'Q3-AE$0:XM(:>VUP=KX:GR
M^WP74N1SX^7TSX_CH+NUDR5I<W[YHFOK)&VY=;F*HH`:B)VX-)+-`ZA*0/=/
M#>2+YF#=ZXT_#^7K!83=O[&M(UYM]1(\C476Q%6O6<K/$%I<BSLT/X%IJTC?
M*\Z3D7)4$&Q/-%(MT).R&JLS9SSWU[/'#,Z06+&Q.:#_`!0YY&T@C5I<TU/3
MS?*MCX-F\9C\)@K*\O;*.V^\4\MY')0D6<D5JQW=!8ZK)&PS-+!4N\E6U+"%
M)M&+<M9"V*MEHRPUV)&@V7'FK4[KD[Q&>'A)#'ESI$O-V#+U9M[B106/C.RS
M=J5C'$L\64;L9RO'/&G66\J=L,\UK=W%_P!ZZ%UVG1PF+MAH+7-)+PXNUC)=
M0N-0',JTDTHJRTRV&QO&HK3#G&?:$5S?MO1<;G-FBE:UEN^,-/T[&1[Q&T`N
MBF`E#6[PY<]:PC8V&8^XGEY_B#-%FFV=GD[+K!!CE*T4:.O#.8U8JM+N\!BV
M2)=%(>EN;WE&-ED?-/&K8C-X9G*()D%%LJ26*Q(N[^[,,[I@YQB&]S0X&(-<
M&'=1I<_=K33RN'0+TNL];287C6&9>V,5NZ)K+Y_8CE=$6WTDL3YV]K=*(H'1
MG:USBYN^)Q.YP+*,FU[--4U-[D+VXXURUB^F6O27&.2,8IIKOJ?7:%E+'=.O
M,=>HNNKH9)GKO!7ME)(UX5)%^NB_GC,//.#='(34XBNXL??_`!$,L<+[5CV:
M;6L>QKMU/.7!U=NI\S]NYVE*[UC;G!WG+N,MLKJSN[Z'.S0SZ"1\L$TL3HG/
M!@9$Z(M,U&,!9#O[;=>B]9-P[L_.J[;N].ZSD[#5-L^J>.JC"5JVS#FGS-\V
M)C<ARDO>)S&J-DG),U9MCC!ZBM?<6E15JSE9M^P5\RX]WJ.R9DMGD'LNOLAD
ML,+[5C0'$M+I=U7%E2:.[=6E^@+B-30E:_C,WQ6W&'9S66UOKZ++S2.?&T2-
MBLW0M;$R8L8W?&+JDP@`<Z.)L@VM[@850R+AR>9X9=6;"%6V9.O%;7:JYP<4
MVSG2KD_%56C7_&J69([%&.HA2NO&D2YQI$/_`'M#&3\"PR"CU1LDY4<"=:66
MQ>+'=9LNB674,E'T:0&N9W.VQNV@V5W"E'&I%:U55CLW;OS@M,]+BMK\1?VH
MDCJ]CI)89_AC<3.W@N$[F=N2M86!@<6AM&I59,392O>,,_EL6!\O.X>+[HF#
M=C:31[#UR<]+8`CI[7N8N4S0(LUG7-X`(0]H>K5U)9N[:+++HE:E<'*08I[2
M6ZLYFOMIMC<BR4,<"28RYA<6C=K4;B6`U%:4!5M:YC$X[+8XVV0LQ,_BMU9R
M2L\K&W99=MC;,[MCQ=`T3$%K@&N+RT$K8LLX^V9?6SN*IX+H^7:R%_Q[IH\Q
M<HM,*5ME;&]!E9@NQE*QA-R%C<1U/OM@Q?(%AF[E,8U%:24(HFYZD#NDYKB&
M_<Z_98QS,WL@+>K=P;3NM8ZM`XM\HH1KT/BL7$9'B\=IQHY^>RE^'N,D)_+O
M,9E:WX.6=@8'21,G'<+3O(8""VC@T[CL5BJ5L6'D4M;,=9FQ\Y<9,E<A-ZM9
MJ;:9_'MCF6^%)6K*56[XL_'5<R%0Z+8S^`T925:4CG<-=/!GDD52E<NE&0M3
M+:;;"&XC:92ZA:2TGM$4<S<'-:>@<VA;)YP/%8?&LM%;9HNY-=6-RT6K83(R
M1C)F--TV3?%/VGPRRLU<YDX>V2VW6Y(JU@RNZUA;-6QO:$V;PCC3&4I.9UR3
MKO7H"%Q1&3\?,ROXQ.]J#V3JS>SRSV/CYE>)4:.$S/EETRN@0%7GS.`#M=L'
MBVC$C=LFQM16M#05%?&ATKX]5R?(]C[0G^&D[MMWG['[=F]NX[7;/V-PH=O[
M-:>"\R'^[J=ZK^P%E3^DN*OZP.)UAH_NZG>J_L!94_I+BK^L#@B/[NIWJO[`
M65/Z2XJ_K`X(O2YI6O6:(SL0U;5M_C^7;;`,NVE$88=XQ.YB33B&4$,#(59:
MG&=IR)X09%.P%%L*@.A;=8<P4Z?O<8UX'.M)&M!+BQU`.IT\%TGT;S.,X[ZL
M\;SV:F;;XBSS=G--*X$MCBCN&/>\AH+J-:"30$^P%59^WIVE.XSB+>74[*&1
M]5;U5:%0L[8]M%OLCZ7HRS."@(F=;.9*4=),;8[>*(,VY!.8$DE#B`>HHCZN
M-)@M;XW4!,$H:V9A)(H``=2=?!?6KUN_,IZ&\F](N1\?P7(K.XS%YA[F*&)K
M)PZ21\3FM8"Z$"KB0!4@>TA>@\/RC^V/&_GJOB8L_@BXC^%U??\`E_X7^YZN
M"+X]AZ=?!$>P].O@B/8>G7P1'L/3KX(CV'IU\$1[#TZ^"(]AZ=?!$>P].O@B
M/8>G7P1'L/3KX(CV'IU\$3>=K_T`?JZY9_6?\Q^K[^%'GZ6_!_'GE_P7U)^]
M_>WZ./\`G;[A\'\^\#V7ENOQ_8]?%?E?@O@)/M'=\%3STW]/E[?FI[?"G72J
MV3B'W@^\EI]U*?>+NCX>O:KW/V=O>^CWU]RNNZFWS42W5[W1^'X'W5[P]U>Y
M8KW9[W]]>]O=WD4/(^]/Q!_G_P!X^5Z/'\]_EGB<_&]IU<9D.SLL[=>WM%*U
MK2FE=WFK3K77VZJBNNY\3)WMO>[CMVW;MW5-=NSR4KTV>6GNZ47<>P].OB10
M(]AZ=?!$>P].O@B/8>G7P1'L/3KX(CV'IU\$1[#TZ^"(]AZ=?!$>P].O@B/8
..>G7P1'L/3KX(LC@B_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
